Immuron (ASX:IMC) has announced CEO Thomas Liquard has resigned due to personal reasons.
Mr Liquard, who will be replaced in the interim by the company's chief operating and scientific officer Dr Jerry Kanellos, will remain with the company as a contracted consultant for the next three months to assist the Board and management team through a smooth and seamless transition.
The company said Dr Kanellos has made an outstanding contribution to Immuron, its projects and the overall company operations, since his appointment in July 2015.
According to chairman, Dr Roger Aston, “On behalf of the Board of Directors, I would like to thank Thomas Liquard for his efforts as CEO over the past 2 years, including his primary focus of delivering our NASDAQ listing, and we wish him every success in his future endeavors.
"We are exceptionally pleased to announce the appointment of Dr Jerry Kanellos from our executive management team to serve as the interim Chief Executive Officer as in his initial two years with us, Dr Kanellos has made a significant contribution to the company and its technology.
"Dr Kanellos’ role to date ensures he has a wealth of knowledge and experience across many areas of the company including Manufacturing, Marketing, Medical Research, New Product Development, Regulatory Affairs, Sales and Quality which will allow him to make a smooth transition to interim-CEO position.
"Immuron now has a solid footing with its anti-infective and anti-inflammatory pipeline which will allow us multiple shots on goal which will culminate across multiple milestones over the next 12 month. We look forward to Dr Kanellos assisting us to continue pushing our strategy and pipeline forward.”
Immuron said it will be embarking on a global search for its next permanent CEO.
Immuron has several ongoing clinical trials in both fatty-liver diseases (NASH, ASH and Ped NASH) and Clostridium difficile infections (CDI), along with a research collaboration with the US Army and the US Navy targeting multiple pathogens.